HZOL can reverse LPS-induced changes relating to the inflammatory cytokines and immune dysfunction and attenuating the expressions of TLR4, CD14, MyD88, NF-κB p65, and p-NF-κB p65 of the TLR4/NF-κB p65 pathway. The gene discussed is NFKB1; the disease is immune system disorder.